1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
Autor: | K. Wu, Kaushal Parikh, Georgia Kollia, U. Guha, R. Sarmiento, Ben Markman, Neal Ready, C. He, Bruce S. Fischer, Atilio Navarro, S. Tannenbaum-Dvir, K. Sanghavi, Y. Liu, Q. Chu, Luis Paz-Ares, Han Chang |
---|---|
Rok vydání: | 2021 |
Předmět: | |
Zdroj: | Annals of Oncology. 32:S1170 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |